Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for WAVE Life Sciences Ltd. (WVE : NSDQ)

• Company Description    WAVE Life Sciences Pte. Ltd. is a preclinical biopharmaceutical company. It designs, develops and commercializes nucleic acid therapeutic candidates for Huntington's disease, Duchenne muscular dystrophy and inflammatory bowel disease. Huntington's disease, the Company has programs targeting HTT SNP-1 and HTT SNP-2; DMD, targeting Exon 51 and in IBD, it is targeting SMAD7. The Company has late-stage discovery programs in epidermolysis bullosa simplex, in which it is targeting KRT14 SNP-1 and KRT14 SNP-2 and in DMD, it is focused on an additional DMD target, Activin Receptor type IIb. WAVE Life Sciences Pte. Ltd. is based in Singapore. Number of Employees: 288

• Price / Volume Information    Yesterday's Closing Price: $17.00 Daily Weekly Monthly 20 Day Moving Average: 13,487,922 shares Shares Outstanding: 167.18 (millions) Market Capitalization: $2,842.09 (millions) Beta: -1.82 52 Week High: $21.73 52 Week Low: $5.28 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 123.10% 123.48% 12 Week 107.57% 104.22% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 7 STRAITS VIEW #12-00 MARINA ONE EAST TOWER - SINGAPORE,U0 018936 SGP ph: 65-6236-3388 fax: 617-949-2901 investorrelations@wavelifesci.com http://www.wavelifesciences.com

• General Corporate Information    Officers Paul B. Bolno - Chief Executive Office; President and Director Christian Henry - Chairman of the Board of Directors Kyle Moran - Chief Financial Officer Aik-Na Tan - Director Adrian Rawcliffe - Director Peer Information WAVE Life Sciences Ltd. (CORR.) WAVE Life Sciences Ltd. (RSPI) WAVE Life Sciences Ltd. (CGXP) WAVE Life Sciences Ltd. (BGEN) WAVE Life Sciences Ltd. (GTBP) WAVE Life Sciences Ltd. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: Y95308105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/03/26 Share - Related Items Shares Outstanding: 167.18 Most Recent Split Date: (:1) Beta: -1.82 Market Capitalization: $2,842.09 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.33 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.29 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 21.72 Price/Cash Flow: - Price / Sales: 26.02 EPS Growth vs. Year Ago Period: 31.91% vs. Previous Quarter: -3.23% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -12.54% ROE 12/31/25 - - 09/30/25 - -75.61 06/30/25 - -78.45 ROA 12/31/25 - - 09/30/25 - -43.00 06/30/25 - -41.51 Current Ratio 12/31/25 - - 09/30/25 - 2.51 06/30/25 - 2.56 Quick Ratio 12/31/25 - - 09/30/25 - 2.51 06/30/25 - 2.56 Operating Margin 12/31/25 - - 09/30/25 - -111.64 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - -111.64 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - -111.64 06/30/25 - -138.24 Book Value 12/31/25 - - 09/30/25 - 0.78 06/30/25 - 0.88 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 5.95 06/30/25 - 5.35

Powered by Zacks Investment Research ©